C14orf93 Inhibitors
The inhibition of C14orf93 involves a diverse array of compounds that target critical cellular pathways, indirectly impacting its activity. Certain kinase inhibitors play pivotal roles; some compounds halt the progression of the cell cycle by selectively targeting specific cyclin-dependent kinases, which are essential for cell cycle regulation in which C14orf93 is implicated. Other compounds target the DNA repair mechanism, impeding the poly (ADP-ribose) polymerase, which indirectly affects the activity of C14orf93 by compromising the DNA repair process, a system where C14orf93 might play a role. Histone acetylation modifiers also contribute to the regulation of C14orf93 by altering chromatin structure and gene expression patterns, potentially affecting proteins that regulate or interact with C14orf93. Moreover, the inhibition of major intracellular signaling pathways, such as the mTOR pathway, by specific compounds can disrupt cellular growth and proliferation processes, leading to an indirect reduction in C14orf93 function.
Further indirect inhibition is achieved through compounds that interfere with proteasome function, leading to an accumulation of proteins that could suppress C14orf93 function, and those that induce apoptosis by inhibiting proteins like BCL-2, potentially diminishing the role of C14orf93 in apoptosis regulation. Additional mechanisms involve a compound that disrupts angiogenesis-related tyrosine kinase signaling, which could impinge upon C14orf93's role in cell migration or vascular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
This compound selectively inhibits cyclin-dependent kinases CDK4 and CDK6. Since C14orf93 is involved in cell cycle regulation, inhibition of these kinases results in halted cell cycle progression, consequently reducing the functional activity of C14orf93. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
A PARP inhibitor that impedes DNA repair processes. C14orf93's role in DNA damage response would be indirectly inhibited as the DNA repair is compromised, affecting its activity in the cell. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor which leads to hyperacetylation of histones, altering the expression of genes, including those that could encode proteins that interact with or regulate C14orf93. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that disrupts the mTOR signaling pathway. Since C14orf93 is implicated in cellular growth processes, mTOR inhibition can indirectly inhibit C14orf93 by halting these processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor which blocks the PI3K/AKT pathway, downregulating proteins that are involved in the same processes as C14orf93, thus indirectly affecting its functional activity. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
A MEK inhibitor that blocks the MAPK/ERK pathway, likely altering the function of proteins that interact with or regulate C14orf93's activity in cellular proliferation and apoptosis. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that prevents the degradation of ubiquitinated proteins, causing an accumulation of regulatory proteins that could suppress C14orf93 function. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
A BCL-2 inhibitor that induces apoptosis in cancer cells. Since C14orf93 may be involved in apoptosis regulation, BCL-2 inhibition could indirectly reduce C14orf93 activity through the induction of apoptosis. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
An EGFR inhibitor that can affect cell proliferation pathways. Assuming C14orf93 is associated with these pathways, its activity would be indirectly diminished as a result of EGFR signal transduction disruption. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Another histone deacetylase inhibitor that leads to changes in gene expression. It could indirectly inhibit C14orf93 by modulating the expression of genes that interact with C14orf93. | ||||||